Keywords: Genta, Tesetaxel, Gastric cancer, Ph IIb

Activity of tesetaxel in advanced gastric cancer confirmed

Article | 19 January 2012

US antisense technology-based drug developer Genta (OTCBB: GNTA.OB) has announced positive results from its Phase IIb, confirmatory clinical trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genta

Go to company listing

Related Drugs

tesetaxel

Go to drug listing